Advancing targeted protein degradation for cancer therapy
The human proteome contains approximately 20,000 proteins, and it is estimated that more
than 600 of them are functionally important for various types of cancers, including nearly 400 …
than 600 of them are functionally important for various types of cancers, including nearly 400 …
[HTML][HTML] EZH2: a novel target for cancer treatment
R Duan, W Du, W Guo - Journal of hematology & oncology, 2020 - Springer
Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive
complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of …
complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of …
[HTML][HTML] The long and short non-coding RNAs modulating EZH2 signaling in cancer
S Mirzaei, MH Gholami, K Hushmandi… - Journal of hematology & …, 2022 - Springer
Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in
encoding proteins. However, they participate in developmental and biological processes …
encoding proteins. However, they participate in developmental and biological processes …
EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
Canonically, EZH2 serves as the catalytic subunit of PRC2, which mediates H3K27me3
deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 …
deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 …
[HTML][HTML] Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
Z Niu, R Jin, Y Zhang, H Li - Signal Transduction and Targeted Therapy, 2022 - nature.com
Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Protein lysine methylation is a crucial post-translational modification that regulates the
functions of both histone and non-histone proteins. Deregulation of the enzymes or 'writers' …
functions of both histone and non-histone proteins. Deregulation of the enzymes or 'writers' …
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Cancers adapt to increasingly potent targeted therapies by reprogramming their phenotype.
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …
Here we investigated such a phenomenon in prostate cancer, in which tumours can escape …
[HTML][HTML] Mechanisms of Polycomb group protein function in cancer
V Parreno, AM Martinez, G Cavalli - Cell research, 2022 - nature.com
Cancer arises from a multitude of disorders resulting in loss of differentiation and a stem cell-
like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are …
like phenotype characterized by uncontrolled growth. Polycomb Group (PcG) proteins are …
[HTML][HTML] Dual-specificity RNA aptamers enable manipulation of target-specific O-GlcNAcylation and unveil functions of O-GlcNAc on β-catenin
Y Zhu, GW Hart - Cell, 2023 - cell.com
O-GlcNAc is a dynamic post-translational modification (PTM) that regulates protein functions.
In studying the regulatory roles of O-GlcNAc, a major roadblock is the inability to change O …
In studying the regulatory roles of O-GlcNAc, a major roadblock is the inability to change O …